Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study

Hepatology Research

Volumn 46, Issue 9, 2016, Pages 862-870

  Sun, Wenjing ^a   Cui, Hongli ^a   Li, Ning ^a   Wei, Yanling ^a   Lai, Shujie ^a   Yang, Yang ^a   Yin, Xinru ^a   Chen, Dong Feng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

hepatic fibrosis; meta analysis; non alcoholic fatty liver disease; non alcoholic steatohepatitis; non invasive assessment

Indexed keywords

ADVANCED LIVER FIBROSIS; BARD SCORE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ODDS RATIO; DIAGNOSTIC TEST ACCURACY STUDY; FIB 4 INDEX; GENERAL PATHOLOGICAL PARAMETERS; HUMAN; INTERMETHOD COMPARISON; LIVER FIBROSIS; META ANALYSIS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 84982801607     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12647     Document Type: Review

References (45)

1. Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357–65.
2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99–S112.
3. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004; 2: 1048–58.
4. Sesti G, Sciacqua A, Fiorentino TV, et al. Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PLoS One 2014; 9: e104941.
5. Nalbantoqlu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(27): 9026–37.
6. de Ledinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol 2012; 56(4): 833–9.
7. Boursier J, Cales P. Clinical interpretation of Fibroscan® results: a real challenge. Liver Int 2010; 30(10): 1400–2.
8. Poynard T, Morra R, Halfon P, et al. Meta-analyses of Fibro Test diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.
9. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clini Chem. 2004; 50: 1344–55.
10. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43(6): 1317–25.
11. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846–54.
12. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441–7.
13. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38(2): 518–26.
14. Williams AL, Hoofnaqle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis Gastroenterology 1998; 95(3): 734–9.
15. Fierbinteanu BC, Sporea I, Panaitescu E, et al. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. Ultrasound Med Biol 2013; 39: 1942–50.
16. Kruger FC, Daniels CR, Kidd M, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 20112; 101: 477–80.
17. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatl. 2009; 7: 1104–12.
18. Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol 2012; 12: 14.
19. Francque SM, Verrijken A, Mertens I, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol 2012; 10(10): 1162–8.
20. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
21. Whiting P, Rutjes AW, Dinnes J, et al. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004; 8(25): 1–234.
22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 1996; 24: 289–93.
23. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372–4.
24. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–9.
25. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409–17.
26. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
27. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323(7305): 157–62.
28. Kardaun JW, Kardaun OJ. Comparative diagnostic performance of three radiological procedures for the detection of lumbar disk herniation. Methods Inf Med 1990; 29(1): 12–22.
29. Zomora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
30. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265–9.
31. Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2.
32. Xun YH, Fan JG, Zang GQ, et al. Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease. J Dig Dis 2012; 13(11): 588–95.
33. Demir M, Lang S, Nierhoff D, et al. Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease. J Clin Gastroenterol 2013; 47(8): 719–26.
34. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32–6.
35. Kim BK, Kim do Y, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int 2010; 30: 546–33.
36. Subasi CF, Aykut UE, Yilmaz Y. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. European J Gastroenterology and Hepatology. 2015; 27(2): 137–41.
37. Younossi ZM, Page S, Rafiq N, et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011; 21(4): 431–9.
38. Sakuqawa H, Nakayoshi T, Kobashiqawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11(2): 255–9.
39. Patel K, Shackel NA. Current status of fibrosis markers. Curr Opin Gastroenterol 2014; 30(3): 253–9.
40. Hu L, Lin X, Lu H, et al. An overview of Hedgehog signaling in fibrosis. Mol Pharmacol 2015; 87: 174–82.
41. Alisi A, Nobili V, Ceccarelli S, et al. Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. Expert Rev Mol Diagn 2014; 14(6): L 763–71.
42. Choi SS, Syn WK, Karaca GF, et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem 2010; 285: 36551–60.
43. Chwist A, Hartleb M, Lekstan A, et al. A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study. Pol Arch Med Wewn 2014; 124(12): 704–12.
44. Cermille S, Ruggieri A, Marrero JA, et al. Circulation microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. Plos One 2011; 8(6): e23937.
45. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143(1): 29–36.